Literature DB >> 10578459

Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice.

K E Stevens1, W R Kem, R Freedman.   

Abstract

BACKGROUND: A physiological alteration associated with schizophrenic and manic psychoses is diminished inhibition of the electrophysiological response to repeated auditory stimuli. This deficit also occurs in cocaine addicts. Studies in animals show that such inhibition is decreased by noradrenergic receptor stimulation and that the inhibition is enhanced by nicotinic cholinergic receptor stimulation.
METHODS: C3H mice were treated for 7 days with cocaine. They were then prepared for electrophysiological recording. After the effects of cocaine treatment were observed, they were treated with nicotine agonists.
RESULTS: Chronic cocaine administration markedly diminished inhibition of the hippocampal-evoked response to repeated auditory stimuli. The loss of inhibition was reversed by acute treatment with either nicotine or the selective alpha 7 nicotinic agonist 3-(2,4)-dimethoxybenzylidine anabaseine (DMXB; GTS21). The effects of nicotine showed tachyphylaxis, whereas those of DMXB did not.
CONCLUSIONS: This reversal of cocaine's effect by nicotinic agonists is consistent with previous pharmacological studies of the inhibition of auditory response. Additionally, the ability of nicotinic agonists to reverse a physiological defect associated with psychosis may have therapeutic implications for the neuropsychiatric sequelae of cocaine addiction in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10578459     DOI: 10.1016/s0006-3223(99)00200-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

1.  Nicotine suppresses the P13 auditory evoked potential by acting on the pedunculopontine nucleus in the rat.

Authors:  N Mamiya; R Buchanan; T Wallace; R D Skinner; E Garcia-Rill
Journal:  Exp Brain Res       Date:  2005-03-08       Impact factor: 1.972

Review 2.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

3.  Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors.

Authors:  Kenji Hashimoto; Masaomi Iyo; Robert Freedman; Karen E Stevens
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

4.  Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.

Authors:  Noam D Rudnick; Andrew A Strasser; Jennifer M Phillips; Christopher Jepson; Freda Patterson; Joseph M Frey; Bruce I Turetsky; Caryn Lerman; Steven J Siegel
Journal:  Nicotine Tob Res       Date:  2010-04-15       Impact factor: 4.244

5.  The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine.

Authors:  A Millar; D Smith; J Choueiry; D Fisher; P Albert; V Knott
Journal:  Neuroscience       Date:  2011-02-16       Impact factor: 3.590

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

7.  Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice.

Authors:  Kristin M Wildeboer; Karen E Stevens
Journal:  Brain Res       Date:  2008-06-11       Impact factor: 3.252

Review 8.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

9.  The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components.

Authors:  Patrick M Connolly; Christina Maxwell; Yuling Liang; Jonathan B Kahn; Stephen J Kanes; Ted Abel; Raquel E Gur; Bruce I Turetsky; Steven J Siegel
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.